Purdue scientists aim to use protein power to halt tumor growth

In 2018, approximately 324,000 men died from cancer in the United States. The combination of lung cancer, prostate cancer and colorectal cancer equated to half of those deaths.

Large percentages of each of these cancers can be prevented or treated if caught early. Now, Purdue University scientists have created a new therapy option that may help halt tumor growth in certain cancers such as prostate, which is among the most common types of cancer in men.

"We have designed a therapy that can help recruit immune cells to kill cancer and also help repair bone and tissues damaged by tumors," said Marxa Figueiredo, associate professor of basic medical sciences in Purdue's College of Veterinary Medicine, who helped lead the research team and is working with the Purdue Research Foundation Office of Technology Commercialization to patent the innovation. "One of the best features of this technology is that it shows great promise in enabling treatment for many other cancers and diseases that could benefit from halting tumor growth and promoting bone repair."

The therapy technology is presented in the journal Molecular Therapy: Methods & Clinical Development.

The Purdue team used a protein called interleukin-27, or IL-27, which has shown promise in reducing tumor growth and helping stop cancer from spreading in the body. IL-27 is a cytokine, a kind of protein secreted by cells of the immune system that act as chemical messengers and can help the immune system target cancer and other diseases.

Immune cells are naturally attracted to areas of the body with lots of signals that come from proteins such as IL-27. So, with our novel approach of targeting the IL-27 to the tumor or bone cells, we can use these proteins to produce signals that bring healthy cells to areas of the body with cancer or other disease and kill the tumors and begin the process of repairing bone and other musculoskeletal tissues."

Marxa Figueiredo, associate professor of basic medical sciences in Purdue's College of Veterinary Medicine

Figueiredo said the new Purdue therapy technology has applications for people and animals with many different types of cancer, including breast and lung, and other diseases where protein targeting could improve the immune system's response.

Source:
Journal reference:

Figueiredo, M.L., et al. (2020) Ligand-mediated targeting of cytokine Interleukin-27 enhances its bioactivity in vivo. Molecular Therapy: Methods & Clinical Development. doi.org/10.1016/j.omtm.2020.03.022.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop new antibody with potential to treat several types of cancer